🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the infection, according to researchers.

An International Public Health Issue

The sexually transmitted infection are on the rise globally, with figures suggesting more than 82 million instances per year. Particularly high rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the context of growing infection rates, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring showed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Receive Approval

One new antibiotic, alternatively called a brand name, was cleared by the US FDA in December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists hope that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP partnered with the drug firm its industry partner to bring it to fruition.

“This authorization represents a significant shift in the therapy of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Research Study Data and Worldwide Availability

As per findings published in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which combines a dual-drug approach. The research enrolled nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the rights to make available and distribute the drug in numerous developing nations.

Clinicians directly involved have expressed hope. Access to a easy-to-administer therapy such as this is seen as a "critical tool" for managing the epidemic. This is deemed vital to alleviate the strain of the illness for people and to halt the transmission of extremely resistant gonorrhoea worldwide.